Page 36 - 2021_12-Haematologica-web

Acute Myeloid Leukemia
Ferrata Storti Foundation
Haematologica 2021 Volume 106(12):3056-3066
Plasmacytoid dendritic cells proliferation associated with acute myeloid leukemia: phenotype profile and mutation landscape
Loria Zalmaï,1 Pierre-Julien Viailly,2 Sabeha Biichle,3 Meyling Cheok,4
Lou Soret,3 Fanny Angelot-Delettre,3 Tony Petrella,5 Marie-Agnès Collonge- Rame,6 Estelle Seilles,3 Sandrine Geffroy,4,7 Eric Deconinck,8
Etienne Daguindau,8 Sabrina Bouyer,9 Elodie Dindinaud,9 Victor Baunin,10 Magali Le Garff-Tavernier,11 Damien Roos-Weil,12 Orianne Wagner-Ballon,13 Véronique Salaun,14 Jean Feuillard,15 Sophie Brun,16 Bernard Drenou,17 Caroline Mayeur-Rousse,18 Patricia Okamba,19 Véronique Dorvaux,20
Michel Tichionni,21 Johann Rose,22 Marie Thérèse Rubio,23
Marie Christine Jacob,24 Victoria Raggueneau,25 Claude Preudhomme,4,7 Philippe Saas,3 Christophe Ferrand,3 Olivier Adotevi,3 Christophe Roumier,4,7 Fabrice Jardin,2 Francine Garnache-Ottou3 and Florian Renosi3
1Service d’Hématologie Biologique, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France; 2INSERM U1245, Centre Henri Becquerel, Rouen, France; 3Université Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte- Greffon-Tumeur/Ingénierie Cellulaire et Génique, Besançon, France; 4INSERM U837, CHRU Lille, IRCL Laboratoire d'Hématologie, Centre de Biologie Pathologie, Lille, France; 5Department of Pathology, University of Montréal, Hôpital Maisonneuve-Rosemont, Montréal, Quebec, Canada; 6Laboratoire de Génétique Biologie, CHU Besançon, Besançon, France; 7Laboratoire d'Hématologie A, Centre de Biologie Pathologie, Boulevard du Pr Leclercq, Lille, France; 8Service Hématologie, CHU Besançon, Besançon, France; 9Service d’Hématologie Biologique, CHU La Milétrie, Poitiers, France; 10Laboratoire du Groupe Hospitalier de La Rochelle-Ré-Aunis, CH de La Rochelle, La Rochelle, France; 11Laboratoire d’Hématologie, Hôpital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France; 12Service d’Hématologie Clinique, Sorbonne Université, Hôpital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France; 13Département d’Hématologie biologique, Hôpitaux Universitaires Henri Mondor, Assistance Publique-Hôpitaux de Paris (AP-HP), Créteil, France; 14Laboratoire d’Hématologie, CHU de Caen Normandie, Normandie Université, UNICAEN, Caen, France; 15Laboratoire d'Hématologie, CHU Dupuytren, Limoges, France; 16Laboratoire d'Hématologie et Consultations d'Hématologie Biologique, Hôpital Universitaire Carémeau, Nîmes, France; 17Service d’Hématologie, Groupe Hospitalier de la région Mulhouse Sud Alsace, Mulhouse, France; 18Laboratoire d’Hématologie, CHRU Strasbourg, Hôpital de Hautepierre, Strasbourg, France; 19Laboratoire d’Hématologie et Auto-immunité, Hôpital de Mercy, CHR de Metz-Thionville, France; 20Service d’Hématologie de l’Hôpital de Mercy, CHR de Metz-Thionville, France; 21Laboratoire d’Hématologie de l’Hôpital Pasteur, Nice, France; 22Laboratoire d’hématologie, CH du Mans, Le Mans, France; 23Service Hématologie, CNRS UMR7365, Biopôle Université de Lorraine, CHRU Nancy, Vandœuvre-lès-Nancy, France; 24Laboratoire d’Immunologie, CHU Grenoble, La Tronche, France and 25Service de Biologie Médicale, Centre Hospitalier de Versailles A. Mignot, Le Chesnay, France
ABSTRACT
Neoplasms involving plasmacytoid dendritic cells (pDC) include blastic pDC neoplasms (BPDCN) and other pDC proliferations, where pDC are associated with myeloid malignancies: most fre- quently chronic myelomonocytic leukemia (CMML) but also acute myeloid leukemia (AML), hereafter named pDC-AML. We aimed to determine the reactive or neoplastic origin of pDC in pDC-AML, and their link with the CD34+ blasts, monocytes or conventional DC (cDC) associated in the same sample, by phenotypic and molecular analyses (targeted next-generation sequencing, 70 genes). We compared 15 pDC- AML at diagnosis with 21 BPDCN and 11 normal pDC from healthy donors. CD45low CD34+ blasts were found in all cases (10-80% of medullar cells), associated with pDC (4-36%), monocytes in 14 cases (1-10%) and cDC (two cases, 4.8-19%). pDC in pDC-AML harbor a clearly different phenotype from BPDCN: CD4+ CD56– in 100% of cases, most frequently CD303+, CD304+ and CD34+; lower expression of
Correspondence:
FRANCINE GARNACHE-OTTOU
francine.garnache@efs.sante.fr
Received: March 26, 2020. Accepted: September 24, 2020. Pre-published: October 13, 2020.
https://doi.org/10.3324/haematol.2020.253740 ©2021 Ferrata Storti Foundation
Material published in Haematologica is covered by copyright. All rights are reserved to the Ferrata Storti Foundation. Use of published material is allowed under the following terms and conditions: https://creativecommons.org/licenses/by-nc/4.0/legalcode. Copies of published material are allowed for personal or inter- nal use. Sharing published material for non-commercial pur- poses is subject to the following conditions: https://creativecommons.org/licenses/by-nc/4.0/legalcode, sect. 3. Reproducing and sharing published material for com- mercial purposes is not allowed without permission in writing from the publisher.
3056
haematologica | 2021; 106(12)
ARTICLE